Compare HRMY & PLPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | PLPC |
|---|---|---|
| Founded | 2017 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2020 | 2001 |
| Metric | HRMY | PLPC |
|---|---|---|
| Price | $35.34 | $311.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $44.11 | ★ $275.00 |
| AVG Volume (30 Days) | ★ 910.7K | 83.7K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.25% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | 0.55 | ★ 2.14 |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.75 | $17.19 |
| Revenue Next Year | $12.88 | $7.28 |
| P/E Ratio | ★ $65.09 | $152.25 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $139.53 |
| 52 Week High | $40.87 | $414.35 |
| Indicator | HRMY | PLPC |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 35.29 |
| Support Level | $35.05 | $308.87 |
| Resistance Level | $35.47 | $405.84 |
| Average True Range (ATR) | 1.59 | 18.75 |
| MACD | -0.20 | -3.56 |
| Stochastic Oscillator | 46.08 | 0.59 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. The Company's primary products support, protect, connect, terminate, and secure cables and wires. The Company provides helical solutions, connectors, fiber optic and copper splice closures, solar framing applications, and electric vehicle charging station foundations. The Company's customers include public and private energy utilities and communication companies, cable operators, contractors and subcontractors, distributors, and value-added resellers. Geographically, the company operates in four regions: PLP-USA, the Americas, EMEA, and Asia-Pacific.